Voyager Therapeutics (VYGR) AI Stock Analysis

• Market Cap: $269.58M
• Dividend Yield: N/A
• Average Volume (3M): 733.01K
• Price to Earnings (P/E): 5.0
• Beta (1Y): 1.46
• Revenue Growth: -70.38%
• EPS Growth: -683.06%
• Country: US
• Employees: 172
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.57
• Shares Outstanding: 55,468,807
• 10 Day Avg. Volume: 761,573
• 30 Day Avg. Volume: 733,012
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.03
• Enterprise Value/Revenue: 0.17
• Enterprise Value/Gross Profit: 0.17
• Enterprise Value/Ebitda: -0.06
• 1Y Price Target: $16.38
• Price Target Upside: 237.04% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10

• Rating: 58 Neutral
• Price Target: $4.50 ▼(-7.41% Downside)

Voyager Therapeutics' overall stock score is primarily influenced by its financial performance challenges, including negative profit margins and fluctuating cash flows. However, positive technical indicators and strategic corporate events provide some optimism. The valuation remains a concern due to ongoing losses, but the company's participation in industry conferences and strategic advancements offer potential for future growth.

Positive Factors

Strategic Advancements

Voyager's participation in the conference underscores its commitment to advancing its pipeline and strengthening its industry position, which is crucial for long-term growth and competitiveness in the biotech sector.

Innovative Gene Therapy Platform

The proprietary AAV vector platform positions Voyager as a leader in gene therapy for neurological diseases, providing a competitive edge in developing innovative treatments for unmet medical needs.

Non-Dilutive Funding

Non-dilutive funding enhances Voyager's financial stability, allowing it to pursue R&D and clinical milestones without diluting shareholder value, supporting sustainable growth.

Negative Factors

Revenue Volatility

The decline in revenue growth highlights challenges in achieving consistent revenue streams, which can impact long-term financial stability and investment attractiveness.

Negative Profit Margins

Ongoing negative profit margins indicate operational challenges and hinder the company's ability to generate sustainable profits, affecting long-term viability.

Fluctuating Cash Flows

Instability in cash flow management can strain financial resources, limiting Voyager's ability to invest in R&D and strategic initiatives, impacting future growth potential.

Voyager Therapeutics Business Overview & Revenue Model

Company Description

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Voyager Therapeutics generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, which may include upfront payments, milestone payments tied to the achievement of specific development goals, and royalties on product sales. Additionally, the company may receive funding from grants or government programs aimed at advancing research in gene therapy. Their revenue model is heavily dependent on the successful progression of their clinical trials and the commercialization of their therapies, as well as maintaining strong relationships with industry partners to enhance their product pipeline and potential market reach.

Voyager Therapeutics Financial Statement Overview

Summary

Voyager Therapeutics is facing financial challenges with declining revenues and profitability. The balance sheet shows a stable equity position, but increasing leverage and negative cash flows are concerns. The company needs to address operational inefficiencies to improve financial health.

Income Statement

Voyager Therapeutics has experienced significant revenue volatility, with a notable decline in revenue from 2023 to TTM. The gross profit margin has decreased, and the company is currently operating at a net loss, impacting net profit margins negatively. The EBIT and EBITDA margins are also negative, indicating operational challenges.

Balance Sheet

The company maintains a strong equity position with a high equity ratio, suggesting financial stability. However, the debt-to-equity ratio has increased slightly, indicating a rise in leverage. Return on equity is negative due to net losses, which is a concern for profitability.

Cash Flow

Operating cash flow is negative, reflecting cash burn, but the company has managed to maintain a positive free cash flow growth rate in TTM. The operating cash flow to net income ratio is unfavorable due to negative net income, indicating cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	42.58M	80.00M	250.01M	40.91M	37.41M	171.13M
Gross Profit	42.58M	80.00M	245.57M	34.72M	-36.37M	62.38M
EBITDA	-119.17M	-78.56M	126.45M	-44.65M	-68.45M	31.20M
Net Income	-107.93M	-65.00M	132.33M	-46.41M	-66.03M	36.74M
Balance Sheet
Total Assets	322.10M	393.05M	351.28M	159.36M	193.85M	261.58M
Cash, Cash Equivalents and Short-Term Investments	215.59M	266.68M	230.88M	118.85M	132.54M	181.14M
Total Debt	40.20M	43.73M	20.29M	23.13M	44.18M	47.61M
Total Liabilities	78.16M	93.29M	114.96M	100.34M	98.80M	107.26M
Stockholders Equity	243.94M	299.76M	236.32M	59.02M	95.06M	154.32M
Cash Flow
Free Cash Flow	-115.83M	-18.83M	74.66M	-15.00M	-55.13M	-108.81M
Operating Cash Flow	-113.65M	-15.31M	77.92M	-12.51M	-53.52M	-96.72M
Investing Cash Flow	80.28M	-94.86M	-141.64M	-7.34M	65.91M	113.00M
Financing Cash Flow	1.18M	114.02M	33.65M	1.11M	612.00K	3.16M

Voyager Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.86
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VYGR, the sentiment is Positive. The current price of 4.86 is above the 20-day moving average (MA) of 4.36, above the 50-day MA of 3.81, and above the 200-day MA of 3.95, indicating a bullish trend. The MACD of 0.26 indicates Negative momentum. The RSI at 68.32 is Neutral, neither overbought nor oversold. The STOCH value of 81.79 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VYGR.

Voyager Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VYGR	58 Neutral	$269.58M	5.05	-37.26%	―	-70.38%	-683.06%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SLN	46 Neutral	$236.17M	―	-99.23%	―	―	―
RNAC	39 Underperform	$268.86M	―	-938.38%	―	―	―
TNYA	36 Underperform	$264.02M	―	-85.21%	―	―	38.94%
KYTX	36 Underperform	$238.72M	―	-61.29%	―	―	-39.69%
GALT	35 Underperform	$272.26M	―	48.74%	―	―	17.80%

Voyager Therapeutics Corporate Events

Voyager Therapeutics Joins Citi’s Biopharma Conference 2025

Voyager Therapeutics announced its participation in Citi’s 2025 Biopharma Back to School Conference, highlighting its strategic advancements in neurotherapeutics. The company aims to optimize the delivery of therapeutics to the central nervous system through its innovative platforms, and anticipates significant clinical milestones in the coming years. This announcement underscores Voyager’s commitment to advancing its pipeline and strengthening its industry position, supported by substantial non-dilutive funding and collaborations.